Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study

By sjmartinez • August 28, 2024

Borazanci EH, Bahary N, Chung V, Huyck TK, Kio EA, Chiorean EG, Skeel RT, Alese OB, Cardin DB, Fountzilas C, Hanna WT, Leal AD, Lee V, Noonan AM, Philip PA, Wainberg ZA, Pashova H, Mann G, Oberstein PE. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Oncologist. 2024 Aug 26:oyae210. doi: 10.1093/oncolo/oyae210. Epub ahead of print. PMID: 39191530.

Tags: Hematology/Oncology, metastatic pancreatic cancer, nab-paclitaxel, PDAC, Publications, relacorilant

Developing remote patient monitoring infrastructure using commercially available cloud platforms

Cao M, Ramezani R, Katakwar VK, Zhang W, Boda D, Wani M, Naeim A. Developing remote patient monitoring infrastructure using commercially available cloud platforms. Front[...]

INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors

Yi JC, Ballard S, Walsh C, Friedman DN, Ganz PA, Jacobs LA, Partridge AH, Mitchell SA, Leisenring WM, Syrjala KL, Baker KS. INteractive survivorship program[...]

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma

Bitar R, Salem R, Finn R, Greten TF, Goldberg SN, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology. 2024 Nov;313(2):e232875. doi:[...]